SVV-001
Poorly Differentiated Neuroendocrine Carcinomas / High-Grade Neuroendocrine Tumors
Phase 1Active
Key Facts
Indication
Poorly Differentiated Neuroendocrine Carcinomas / High-Grade Neuroendocrine Tumors
Phase
Phase 1
Status
Active
Company
About Seneca Therapeutics
Seneca Therapeutics is a private, pre-revenue biotech focused on advancing its lead asset, SVV-001, an oncolytic virus targeting the TEM8 receptor. The company is currently conducting a Phase 1 clinical trial in neuroendocrine carcinomas and recently secured a $3.9 million Series B extension. Its strategy involves developing SVV-001 as a monotherapy and in combination with established immunotherapies like checkpoint inhibitors.
View full company profile